Hartkopf A, Albert US, Bartsch R, Bauerfeind I, Banys-Paluchowski M, Bjelic-Radisic V, Blohmer JU, Dall P, Fallenberg EM, Fasching P, Friedrich M, Gluz O, Harbeck N, Heil J, Hörner-Rieber J, Huober J, Janni W, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, van Mackelenbergh MT, Mundhenke C, Park-Simon TW, Reinisch M, Reimer T, Rhiem K, Rody A, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thill M, Untch M, Witzel I, Wöckel A, Wuerstlein R, Ditsch N, Fehm T, Müller V, Schmidt M (2026)
Publication Type: Journal article, Review article
Publication year: 2026
Book Volume: 89
Article Number: 104873
DOI: 10.1016/j.breast.2026.104873
Biomarkers are integral to modern breast cancer management by providing essential information for prognosis and treatment selection. This review presents the 2026 update of the recommendations of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) on therapy-relevant prognostic and predictive biomarkers. The recommendations are based on a structured evaluation of the most recent and clinically relevant evidence using the AGO grading system to support decision-making in routine clinical practice.
APA:
Hartkopf, A., Albert, U.S., Bartsch, R., Bauerfeind, I., Banys-Paluchowski, M., Bjelic-Radisic, V.,... Schmidt, M. (2026). AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer—2026 Update. The Breast, 89. https://doi.org/10.1016/j.breast.2026.104873
MLA:
Hartkopf, Andreas, et al. "AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer—2026 Update." The Breast 89 (2026).
BibTeX: Download